Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 3-Year EBITDA Growth Rate is 7.70% as of Mar. 2026, which is 242% above its 10-year median of 2.25. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Phibro Animal Health ranks worse than 51.29% on this metric.
During the past 12 months, Phibro Animal Health's average EBITDA Per Share Growth Rate was 75.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -1.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Phibro Animal Health was 17.70% per year. The lowest was -14.40% per year. And the median was 2.25% per year.
Phibro Animal Health (NAS:PAHC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Phibro Animal Health 3-Year EBITDA Growth Rate Related Terms
PAHC vs PRGO, HROW, XERS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's 3-Year EBITDA Growth Rate falls into.
Phibro Animal Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.70% mean?
Phibro Animal Health (PAHC) has a 3-Year EBITDA Growth Rate of 7.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Phibro Animal Health and its competitors. This is 242% above median its historical median of 2.25. According to the industry distribution chart, Phibro Animal Health ranks #416 out of 811 companies in the Drug Manufacturers industry, placing it in the top 51.3%.
Is Phibro Animal Health's 3-Year EBITDA Growth Rate too high?
Phibro Animal Health's current 3-Year EBITDA Growth Rate of 7.70% is 242% above median its 10-year median of 2.25. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Phibro Animal Health's value of 7.70% is 12.5% below this industry median. Based on the distribution chart, Phibro Animal Health ranks #416 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's 3-Year EBITDA Growth Rate compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #416 out of 811 companies for 3-Year EBITDA Growth Rate. This places Phibro Animal Health in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Phibro Animal Health's value of 7.70% is 12.5% below this benchmark. While the company's 10-year median is 2.25 vs. the industry median of 8.80, Phibro Animal Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current 3-Year EBITDA Growth Rate of 7.70% is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current 3-Year EBITDA Growth Rate is 7.70%, which is 242% above median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.70%, which is 242% above median its 10-year median of 2.25 and 12.5% below the Drug Manufacturers industry median of 8.80. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current 3-Year EBITDA Growth Rate is 7.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
3-Year EBITDA Growth Rate: 7.70% (242% above median its 10-year median of 2.25)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 12.5% below the Drug Manufacturers median (#416 of 811)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
